Evidence map›Paper›PMID 39082171›Full record

ArticleMedicinal chemistry (Shariqah (United Arab Emirates))2025

Ivone Leila Lima Delgado, Caue Benito Scarim, Felipe Hugo Alencar Fernandes, Karina Pereira Barbieri, Marisa Campos Polesi, Aline Renata Pavan, Diego Eidy Chiba, Herida Regina Nunes Salgado, Iracilda Zeppone Carlos, Marcos Antonio Correa and 2 more

Abstract read
PubMed Publisher
In one paragraph

Article in Medicinal chemistry (Shariqah (United Arab Emirates)), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Ivone Leila Lima DelgadoSchool of Pharmaceutical Sciences, São Paulo State University (UNESP), Rod. Araraquara-Jaú, Araraquara, 14800- 903, Brazil.ORCID 0000-0002-2169-1213
Caue Benito ScarimSchool of Pharmaceutical Sciences, São Paulo State University (UNESP), Rod. Araraquara-Jaú, Araraquara, 14800- 903, Brazil.ORCID 0000-0002-2540-6395
Felipe Hugo Alencar FernandesSchool of Pharmaceutical Sciences, São Paulo State University (UNESP), Rod. Araraquara-Jaú, Araraquara, 14800- 903, Brazil.ORCID 0000-0002-7210-4349
Karina Pereira BarbieriSchool of Pharmaceutical Sciences, São Paulo State University (UNESP), Rod. Araraquara-Jaú, Araraquara, 14800- 903, Brazil.ORCID 0000-0002-0497-6380
Marisa Campos PolesiSchool of Pharmaceutical Sciences, São Paulo State University (UNESP), Rod. Araraquara-Jaú, Araraquara, 14800- 903, Brazil.ORCID 0000-0003-1424-5730
Aline Renata PavanSchool of Pharmaceutical Sciences, São Paulo State University (UNESP), Rod. Araraquara-Jaú, Araraquara, 14800- 903, Brazil.ORCID 0000-0002-4932-7720
Diego Eidy ChibaSchool of Pharmaceutical Sciences, São Paulo State University (UNESP), Rod. Araraquara-Jaú, Araraquara, 14800- 903, Brazil.ORCID 0000-0003-2844-6402
Herida Regina Nunes SalgadoSchool of Pharmaceutical Sciences, São Paulo State University (UNESP), Rod. Araraquara-Jaú, Araraquara, 14800- 903, Brazil.ORCID 0000-0002-0385-340X
Iracilda Zeppone CarlosSchool of Pharmaceutical Sciences, São Paulo State University (UNESP), Rod. Araraquara-Jaú, Araraquara, 14800- 903, Brazil.ORCID 0000-0002-0084-3468
Marcos Antonio CorreaSchool of Pharmaceutical Sciences, São Paulo State University (UNESP), Rod. Araraquara-Jaú, Araraquara, 14800- 903, Brazil.ORCID 0000-0002-0902-6675
Cleverton Roberto de AndradeSchool of Dentistry, São Paulo State University (UNESP), R. Humaitá 1680, Araraquara, 14801-385, Brazil.ORCID 0000-0001-7015-7175
Jean Leandro Dos SantosSchool of Pharmaceutical Sciences, São Paulo State University (UNESP), Rod. Araraquara-Jaú, Araraquara, 14800- 903, Brazil.ORCID 0000-0002-2460-2829

Funding

Coordenação de Aperfeiçoamento de Pessoal de Nível Superior - Brasil (CAPES) 001Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP) 2018/19523-7, 2023/05739-6
6 · The paper itself

Abstract

introductionFuroxan and benzofuroxan are compounds containing an

methodTwenty compounds were tested against both Gram-positive and Gram-negative bacteria, including

resultsMeasurements of Interleukin-1 beta (IL1-β) and Tumor Necrosis Factor-alpha (TNF-α) indicated that compound 15 did not reduce the levels of these pro-inflammatory cytokines. Sustained NO production by inducible Nitric Oxide Synthase (iNOS) in macrophages or neutrophils has been found to be involved in the inflammatory process in acne vulgaris and lead to toxicity in surrounding tissues. Nitrite levels in the supernatant of murine macrophages were found to be decreased at a concentration of 0.78 μg/mL of compound 15, indicating an anti-inflammatory effect.

conclusionSimilar results were observed in the benzoyl peroxide group, demonstrating that compound 15 presented comparable anti-inflammatory activity to the FDA-approved drug. These promising results suggest that compound 15 has a dual mechanism of action, with selective antimicrobial activity against

Indexed as

Acne VulgarisAnti-Bacterial AgentsAnimalsHumansMiceMicrobial Sensitivity TestsNitric OxidePropionibacterium acnesRAW 264.7 CellsAnti-Bacterial AgentsNitric Oxideacne vulgaris.anti-inflammatory activityantimicrobial susceptibility testingCutibacterium acnesfuroxannitric oxide

Identifiers

PMID39082171

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.